BRAIN Biotech AG Return on Equity

BRAIN Biotech AG (BNN.DE) currently reports a ROE of 204.79%. That is above the Healthcare sector average of 11.15%. Use the charts on this page to explore BRAIN Biotech AG's ROE history and peer comparisons.

BRAIN Biotech AG's ROE of 204.79% is higher than the Healthcare sector average of 11.15%. That is roughly 1736.0% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but BRAIN Biotech AG's current 204.79% should be judged against Healthcare norms (sector average: 11.15%) and against BNN.DE's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 204.79%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 11.15%. From there, open related valuation or income-statement pages for BRAIN Biotech AG, and consider following BNN.DE for alerts when major investors trade the stock.

BRAIN Biotech AG is classified in the Healthcare sector. On ROE, it currently shows 204.79% versus a sector average near 11.15%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing BNN.DE with unrelated industries.